Reneo Pharmaceuticals Performance
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
Reneo Pharmaceuticals holds a performance score of 41 on a scale of zero to a hundred. The company holds a Beta of 0.18, which implies not very significant fluctuations relative to the market. As returns on the market increase, Reneo Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Reneo Pharmaceuticals is expected to be smaller as well. Use Reneo Pharmaceuticals value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on Reneo Pharmaceuticals.
Risk-Adjusted Performance
41 of 100
Weak | Strong |
Excellent
Compared to the overall equity markets, risk-adjusted returns on investments in Reneo Pharmaceuticals are ranked lower than 41 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady technical indicators, Reneo Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 19.9 M |
Reneo |
Reneo Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,620 in Reneo Pharmaceuticals on September 26, 2024 and sell it today you would earn a total of 200.00 from holding Reneo Pharmaceuticals or generate 12.35% return on investment over 90 days. Reneo Pharmaceuticals is currently generating 1.5011% in daily expected returns and assumes 2.8562% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Reneo, and 71% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Reneo Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Reneo Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Reneo Pharmaceuticals, and traders can use it to determine the average amount a Reneo Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.5256
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | RPHM | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.86 actual daily | 25 75% of assets are more volatile |
Expected Return
| 1.5 actual daily | 29 71% of assets have higher returns |
Risk-Adjusted Return
| 0.53 actual daily | 41 59% of assets perform better |
Based on monthly moving average Reneo Pharmaceuticals is performing at about 41% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Reneo Pharmaceuticals by adding it to a well-diversified portfolio.
Reneo Pharmaceuticals Fundamentals Growth
Reneo Stock prices reflect investors' perceptions of the future prospects and financial health of Reneo Pharmaceuticals, and Reneo Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Reneo Stock performance.
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (15.01 M) | |||
| Shares Outstanding | 3.34 M | |||
| Price To Book | 0.79 X | |||
| EBITDA | (82.23 M) | |||
| Cash And Equivalents | 126.85 M | |||
| Cash Per Share | 5.18 X | |||
| Total Debt | 973 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 2.30 X | |||
| Cash Flow From Operations | (63.68 M) | |||
| Earnings Per Share | (16.80) X | |||
| Total Asset | 107.44 M | |||
| Retained Earnings | (218.47 M) | |||
About Reneo Pharmaceuticals Performance
By examining Reneo Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Reneo Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Reneo Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company was incorporated in 2014 and is headquartered in Irvine, California. Reneo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.Things to note about Reneo Pharmaceuticals performance evaluation
Checking the ongoing alerts about Reneo Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Reneo Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Reneo Pharmaceuticals is now traded under the symbol OKUR. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Reneo Pharmaceuticals is not yet fully synchronised with the market data | |
| Reneo Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Reneo is showing solid risk-adjusted performance over 90 days | |
| Reneo Pharmaceuticalshas 3,398,311 shares shorted by Reneo Pharmaceuticals investors is about 100% of outstending shares | |
| Net Loss for the year was (77.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Reneo Pharmaceuticals currently holds about 126.85 M in cash with (63.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.18. | |
| Over 88.0% of the company shares are owned by institutional investors |
- Analyzing Reneo Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Reneo Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Reneo Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Reneo Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Reneo Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Reneo Pharmaceuticals' stock. These opinions can provide insight into Reneo Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |